Rotigotine

Rotigotine is a potent dopamine receptor agonist with Ki values of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors and dopamine D1 receptor. Rotigotine a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor. Rotigotine can be used for parkinson's disease (PD) research[1][2][3][4].

Product Specifications

CAS Number

[99755-59-6]

Product Name Alternative

N-0923; (-) -N 0437

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

5-HT Receptor; Adrenergic Receptor; Dopamine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease; Endocrinology

Assay Protocol

https://www.medchemexpress.com/rotigotine.html

Purity

99.99

Solubility

DMSO : ≥ 50 mg/mL

Smiles

CCCN(CCC1=CC=CS1)[C@H]2CCC3=C(C=CC=C3O)C2

Molecular Formula

C19H25NOS

Molecular Weight

315.47

Precautions

H302, H315, H319

References & Citations

[1]Wood M, et, al. Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors. Br J Pharmacol. 2015 Feb;172 (4) :1124-35.|[2]Radad K, et, al. Neuroprotective effect of rotigotine against complex I inhibitors, MPP⁺ and rotenone, in primary mesencephalic cell culture. Folia Neuropathol. 2014;52 (2) :179-86. |[3]Bertaina-Anglade V, et, al. Antidepressant properties of rotigotine in experimental models of depression. Eur J Pharmacol. 2006 Oct 24;548 (1-3) :106-14.|[4]Scheller D, et, al. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379 (1) :73-86.